Quantification of Unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples
Raquel Buj(Penn State Milton S. Hershey Medical Center), Mireia Jordà(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Izaskun Mallona(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Miguel A. Peinado(Badalona Serveis Assistencials), Jordi L. Reverter(Universitat Autònoma de Barcelona), Manuel Perucho(Sanford Burnham Prebys Medical Discovery Institute), Gabriel Capellá(Institut Català d'Oncologia), Rafael Rosell(Hospital Universitario Dexeus), Sergio Alonso(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Xavier Matías‐Guiu(Universitat de Lleida), Manel Puig‐Domingo(Universitat Autònoma de Barcelona), Anna Díez-Villanueva, Víctor Barrera(Boston University), Daniel Azuara(Bellvitge University Hospital), José Luis Ramírez(Institut Català d'Oncologia), Dı́dac Mauricio(Universitat de Vic - Universitat Central de Catalunya)
Cited by 19
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k